Aerie Pharmaceuticals Inc (NASDAQ:AERI) – Analysts at Cantor Fitzgerald issued their FY2017 earnings estimates for Aerie Pharmaceuticals in a report released on Tuesday, according to Zacks Investment Research. Cantor Fitzgerald analyst E. Piros anticipates that the company will earn ($3.23) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $56.00 target price on the stock.
Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings results on Tuesday, March 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by $0.20.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.com-unik.info/2017/04/21/brokers-offer-predictions-for-aerie-pharmaceuticals-incs-fy2017-earnings-aeri-updated-updated.html.
Several other research analysts have also commented on AERI. Canaccord Genuity set a $56.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, March 11th. Stifel Nicolaus restated a “buy” rating and set a $65.00 price target on shares of Aerie Pharmaceuticals in a research note on Tuesday. Aegis restated an “in-line” rating and set a $63.00 price target on shares of Aerie Pharmaceuticals in a research note on Wednesday, March 8th. Needham & Company LLC restated a “buy” rating and set a $58.00 price target (up previously from $52.00) on shares of Aerie Pharmaceuticals in a research note on Wednesday, March 8th. Finally, Cowen and Company restated an “outperform” rating and set a $70.00 price target on shares of Aerie Pharmaceuticals in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Aerie Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $57.62.
Aerie Pharmaceuticals (NASDAQ:AERI) traded down 2.37% during trading on Thursday, reaching $41.20. 299,949 shares of the company were exchanged. The company’s 50-day moving average price is $45.75 and its 200-day moving average price is $41.37. The stock’s market capitalization is $1.39 billion. Aerie Pharmaceuticals has a 1-year low of $12.56 and a 1-year high of $51.85.
In other Aerie Pharmaceuticals news, Director Gerald D. Cagle purchased 2,000 shares of the firm’s stock in a transaction dated Wednesday, April 19th. The shares were purchased at an average cost of $41.70 per share, with a total value of $83,400.00. Following the completion of the purchase, the director now owns 10,900 shares in the company, valued at approximately $454,530. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Geoffrey M. Duyk sold 41,591 shares of the firm’s stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $46.63, for a total transaction of $1,939,388.33. Following the completion of the transaction, the director now directly owns 10,067 shares in the company, valued at $469,424.21. The disclosure for this sale can be found here. 8.77% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the company. Columbus Circle Investors increased its position in Aerie Pharmaceuticals by 20.8% in the first quarter. Columbus Circle Investors now owns 282,309 shares of the company’s stock valued at $12,803,000 after buying an additional 48,689 shares in the last quarter. Fox Run Management L.L.C. increased its position in Aerie Pharmaceuticals by 49.3% in the first quarter. Fox Run Management L.L.C. now owns 9,558 shares of the company’s stock valued at $433,000 after buying an additional 3,158 shares in the last quarter. Teachers Advisors LLC increased its position in Aerie Pharmaceuticals by 23.9% in the fourth quarter. Teachers Advisors LLC now owns 47,324 shares of the company’s stock valued at $1,791,000 after buying an additional 9,127 shares in the last quarter. Senzar Asset Management LLC acquired a new position in Aerie Pharmaceuticals during the fourth quarter valued at $7,150,000. Finally, AQR Capital Management LLC acquired a new position in Aerie Pharmaceuticals during the fourth quarter valued at $973,000. 95.69% of the stock is currently owned by hedge funds and other institutional investors.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Aerie Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aerie Pharmaceuticals Inc and related companies.